Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

• Niels W. C. J. van de Donk,
• Nizar Bahlis,
• Luciano J. Costa,
• María-Victoria Mateos,
• Ajay K. Nooka,
• Aurore Perrot,
• Alfred L. Garfall,
• Pragya Thaman,
• Keqin Qi,
• Clarissa Uhlar,
• Katherine Chastain,
• Margaret Doyle,
• Saad Z. Usmani

Affiliations

Niels W. C. J. van de Donk

Amsterdam University Medical Center, Vrije Universiteit Amsterdam

Nizar Bahlis

Arnie Charbonneau Cancer Institute, University of Calgary

Luciano J. Costa

University of Alabama at Birmingham

María-Victoria Mateos

University Hospital of Salamanca/IBSAL/CIC/CIBERONC

Ajay K. Nooka

Winship Cancer Institute, Emory University

Aurore Perrot

Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole

Alfred L. Garfall

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

Pragya Thaman

Janssen Research & Development

Keqin Qi

Janssen Research & Development

Clarissa Uhlar

Janssen Research & Development

Katherine Chastain

Janssen Research & Development

Margaret Doyle

Janssen Sciences Ireland

Saad Z. Usmani

Memorial Sloan Kettering Cancer Center